BrainswayBWAY
Recorded

Brainsway 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration34 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, everyone. My name is Donna, and I will be your conference operator today. At this time, I would like to welcome everyone to BrainsWay's third quarter 2026 financial results conference call. All lines have been placed on mute to prevent any background noise. With us today are BrainsWay Chief Executive Officer, Hadar Levy, and Chief Financial Officer, Ido Marom. The format of today's call will be a discussion of recent trends and business updates from Hadar, followed by a detailed discussion of the financials. Then we will open the call for your questions. Earlier today, BrainsWay released its financial results for the three and nine months ended September 30, 2026. A copy of the press release is available on the company's investor relations website, www.brainsway.com.

Operator

Before I turn the call over to management, I would like to remind you that this conference call, including both management's prepared remarks and the question-and-answer session, may contain projections or other forward-looking statements regarding, among other topics, BrainsWay's anticipated future operating and financial performance, business plans and prospects, and expectations for its products and pipeline, which are all subject to certain risks and uncertainties, including shifting market conditions resulting from geopolitical supply chain and other risk factors, as well as the use of non-IFRS financial information. Additional information regarding these and other risk factors is available in the company's earnings release and its other filings with the SEC, including the risk factor section contained in BrainsWay's Form 20-F. I will now like to turn the call over to Hadar.

Hadar LevyCEO

Thank you, operator, and welcome, everyone. I am pleased to report another strong quarter for BrainsWay, reflecting continued execution of our growth strategy, expanding adoption of Deep TMS, and further progress toward building a scalable and profitable business. Our ambition extend beyond selling medical devices. We are building a leading neurostimulation platform in mental health, supported by differentiated technology, expanding clinical indication, broader reimbursement, strategic partnership, and increasingly predictable recurring revenue model. During the third quarter, we shipped 130 Deep TMS systems, representing 44% year-over-year growth. Our global install base now exceed 2,000 systems, further expanding patient access to Deep TMS while creating additional opportunities for commercial leverage across our existing customers. Our financial results reflect this momentum, with revenue growing 34% year-over-year and remaining performance obligation reaching approximately $85 million, an increase of 31% compared with the prior year.

Hadar LevyCEO

We believe the continued growth in RPO demonstrates both strong market demand and the success of our recurring revenue model. Our multi-year agreements, high customer retention, and growing enterprise relationship provide greater visibility into future revenue while allowing us to deliver comprehensive, high-quality support to our customers. Importantly, we continue to demonstrate our ability to combine strong growth with operational discipline and profitability. Turning to clinical development, Deep TMS continue to build on one of the industry's most extensive bodies of peer-reviewed evidence, supported by multiple FDA clearances. During the quarter, we announced a peer-reviewed secondary analysis of our randomized clinical trial comparing SWIFT with standard once-daily Deep TMS. Among 89 patients with major depressive disorder, the number experienced suicidal ideation declined from 20 at baseline to six after six weeks, representing a 70% relative reduction with improvements observed across both protocols.

Hadar LevyCEO

We also announced encouraging results from a pilot study involving 12 patients with depression and early-stage Alzheimer's disease, reporting an 83% response rate and 50% remission rate in depressive symptoms. While preliminary, these findings support further investigation. Deep TMS is not FDA cleared for suicidal ideation or to treat Alzheimer's disease. Regarding PTSD, among patients with coexisting depression, we continue to work through the regulatory review process. We believe a potential clearance would represent an important development, potentially allowing providers to address another significant unmet medical need using their existing Deep TMS systems. Alongside these clinical advances, we continue to make significant progress in reimbursement. Following the quarter, we announced that more than 70 million covered lives in the U.S. now have access to reimbursement policies covering our SWIFT accelerated protocol.

Hadar LevyCEO

We have also extended OCD reimbursement coverage to approximately 180 million lives, while our adolescent depression clearance creates another opportunity to broaden access. We believe SWIFT represents one of our most significant long-term growth opportunities. By reducing the acute phase of treatment from several weeks to just few days, SWIFT has a potential to improve patient convenience, increase treatment capacity for providers, and strengthen the overall economics of Deep TMS treatment. Together, these clinical and reimbursement advances reinforce our competitive position and support greater utilization across our expanding install base. Turning to our commercial strategy, we are seeing growing interest from large behavioral health organizations seeking comprehensive technology partners to support expansion across multiple locations. Our differentiated clinical portfolio, accelerated treatment capabilities, and high-touch customer support position BrainsWay as an attractive long-term partner.

Hadar LevyCEO

We believe this enterprise relationship represents an important opportunity to broaden access to Deep TMS, accelerate system deployment, and ultimately extend recurring revenue. Our strategic minority investment program complements this strategy by partnering with behavioral health providers. During the quarter, we invested $3 million in Radial Health Series A financing, building on our existing relationship with other providers such as Heading Health. Radial is developing an integrated mental health services platform, and we believe this partnership creates meaningful opportunities for commercial and clinical collaboration. Following the quarter, we also announced a strategic commercial collaboration with Inland Psychiatric Medical Group, including a multi-system Deep TMS order and opportunities for future clinical and research initiatives. We continue to see a strong pipeline of enterprise partnership and potential investment, while remaining disciplined in selecting opportunities that offer both strategic value and attractive financial returns.

Hadar LevyCEO

Beyond our core business, we continue to invest in next-generation Deep TMS technology and opportunities to expand access to neurostimulation. Through our strategic investment in Neurolief, we are also participating in the emerging home-use-based neurostimulation market. While commercialization of its FDA-approved Proliv Rx system remains at early stage, we believe this technology could complement our clinic-based platform over the longer term. Our broader vision is to connect advanced clinic-based treatments with innovative home-use solutions, creating a more comprehensive neurostimulation platform. As we look toward 2027, we believe BrainsWay is entering its next phase of growth. We see multiple complementary opportunities: expanding our install base, increasing utilization through SWIFT and potential additional indications, scaling enterprise partnerships, and strengthening our international presence. Importantly, our growing recurring revenue base and scalable operating model provide a strong foundation for sustained growth and expanding profitability.

Hadar LevyCEO

In closing, I am pleased with our third-quarter performance and even more encouraged by the opportunities ahead. We have built a differentiated technology platform, established a strong clinical foundation, expanded reimbursement, and developed a business model designed for sustainable growth. Our ambition is not simply to participate in the growth of interventional psychiatry. Our ambition is to help shape its future. We remain focused on expanding patient access, improving outcomes, and creating long-term value for our shareholders. With that, I will turn the call over to Ido for a detailed review of our third-quarter financial results.

Ido MaromCFO

Ido. Thank you, Hadar. During the third quarter of 2026, we continued to execute on our growth strategy, leading to a 34% increase in revenue to $18.1 million compared with $13.5 million in the same period last year.

Ido MaromCFO

For the first nine months of 2026, revenue increased 35% to $50.8 million. Gross profit for the quarter increased 39% to $14.1 million compared with $10.2 million last year, while gross margin reached 78% compared with 75% both last year and in the second quarter of 2026. Turning to operating expenses. Sales and marketing expenses for the third quarter totaled $5.5 million compared with $4.7 million in the third quarter of 2025. Research and development expenses were $3.5 million compared with $2.4 million last year. General and administrative expenses were $2.5 million compared with $1.8 million last year.

Ido MaromCFO

Total operating expenses were $11.5 million compared with $8.9 million in the third quarter of 2025. Compared with the same period last year, operating expenses this quarter included approximately $1 million in additional one-time expenses related to share-based compensation and other non-recurring payments. This increase reflects also the expanding scale of our business and continued investment in our commercial, clinical, and product development plans. Revenue growth continued to outpace operating expenses growth, enabling us to support these initiatives while improving operating leverage. Operating income increased 107% to approximately $2.6 million compared with $1.3 million in the third quarter of 2025. Operating margin expanded to 14% of revenue from 9%. For the first nine months of 2026, operating income increased to 190% to approximately $7 million, with operating margin reaching 14% compared with 6% last year.

Ido MaromCFO

These results demonstrate our continued ability to translate growth into higher profits and stronger margins. Net income for the third quarter increased 42% to $2.2 million compared with $1.6 million in the same period of 2025. It is important to highlight that during the quarter, we incurred finance expenses related to the periodic valuation of our loan. These valuations reflect various market factors, including changes in adjusted interest rates. These accounting adjustments impacted our reported net income, but do not reflect the underlying performance of our core operations. Adjusted EBITDA was $3.9 million, an increase of 92% compared with $2 million in the third quarter of 2025. Adjusted EBITDA margin expanded to 21% from 15% adjusted EBITDA from 15%. Adjusted EBITDA also increased 11% compared with the second quarter of 2026.

Ido MaromCFO

Remaining performance obligation grew to approximately $85 million as of September 30, 2026, a 31% year-over-year increase. This growth supports our visibility into future revenue and reflects continued executions against our long-term strategy. Cash flow from operation was approximately $6.2 million in the third quarter, compared with approximately $1.4 million in the prior year period. Collection more than doubled year-over-year, reflecting $21.3 million and increased approximately 8% compared with the second quarter, reflecting our continued focus and cash generation. Our cash balance increased $63.4 million as of September 30, 2026, while we continued to invest for future growth. Our strong capital position supports the continued development of our core business and the disciplined execution of our strategic investment program.

Ido MaromCFO

Looking ahead, based on our strong performance and increased visibility into the remainder of the year, we now expect full year 2026 results to be at the upper end of our previously issued guidance range, with the potential to modestly exceed those ranges. This concludes my prepared remarks, and I will now turn the call back to the operator to please open up the call for questions.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day